WallStSmart

Merck & Company Inc (MRK)vsOwlet Inc (OWLT)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 58791% more annual revenue ($67.38B vs $114.41M). MRK leads profitability with a 3.6% profit margin vs -8.4%. MRK earns a higher WallStSmart Score of 44/100 (D).

MRK

Hold

44

out of 100

Grade: D

Growth: 3.3Profit: 6.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

OWLT

Hold

37

out of 100

Grade: F

Growth: 6.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 4/9Altman Z: -4.25
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-72.9%)

Margin of Safety

-72.9%

Fair Value

$84.87

Current Price

$146.73

$61.86 premium

UndervaluedFair: $84.87Overvalued

Intrinsic value data unavailable for OWLT.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$368.89B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
41.2%10/10

Strong operational efficiency at 41.2%

Free Cash FlowQuality
$5.52B8/10

Generating 5.5B in free cash flow

OWLT2 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
29.9%8/10

Revenue surging 29.9% year-over-year

Areas to Watch

MRK4 concerns · Avg: 3.5/10
Price/BookValuation
8.6x4/10

Trading at 8.6x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Return on EquityProfitability
5.5%3/10

ROE of 5.5% — below average capital efficiency

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

OWLT4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$121.85M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-526.0%2/10

ROE of -526.0% — below average capital efficiency

Free Cash FlowQuality
$-631,0002/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : OWLT

The strongest argument for OWLT centers on Debt/Equity, Revenue Growth. Revenue growth of 29.9% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Bear Case : OWLT

The primary concerns for OWLT are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while OWLT is a growth play — different risk/reward profiles.

OWLT carries more volatility with a beta of 2.22 — expect wider price swings.

OWLT is growing revenue faster at 29.9% — sustainability is the question.

MRK generates stronger free cash flow (5.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (44/100 vs 37/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Owlet Inc

HEALTHCARE · MEDICAL DEVICES · USA

Owlet Inc. is a leading innovator in infant health technology, dedicated to enhancing the safety and wellness of newborns through its state-of-the-art monitoring solutions. The company's flagship product, the Owlet Smart Sock, employs advanced pulse oximetry to provide parents with real-time insights into their infants' heart rates and oxygen levels via mobile devices. With growing demand for pediatric health monitoring solutions, Owlet is well-positioned to expand its product offerings and fortify its market presence. The company's focus on delivering actionable health information and improving pediatric care aligns with institutional investors' interests in the dynamic health technology sector.

Want to dig deeper into these stocks?